Related Experiment Videos
Ewing's sarcoma and peripheral primitive neuroectodermal tumor
1Klinik und Poliklinik für Kinderheilkunde, Münster, Germany.
Abstract:
Disease-free survival for patients with small sarcomas of bone has been impressively improved with the use of intensive combination chemotherapy and safe local control with surgery or radiation. The ability of monoclonal antibodies to recognize different antigens has allowed new insights into the histogenesis and has distinguished a neural variant now referred to as malignant peripheral neuroectodermal tumor. Both entities share the translocation t(11;22) (q24;q12) as a constant phenomenon. The breakpoint region has now been cloned, allowing for molecular identification and detection of tumor cells and opening a new era of diagnostic and staging possibilities. Patients with disseminated disease, either at diagnosis or in relapse, have benefitted from megatherapy regimens followed by bone marrow or peripheral stem cell rescue. However, this approach is still under investigation and remains to be standardized.
Insights
Intensive chemotherapy and local control improve survival for small bone sarcomas. Molecular detection of the t(11;22) translocation aids diagnosis and staging for these tumors, including malignant peripheral neuroectodermal tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small bone sarcomas have seen improved outcomes with current treatments.
- Monoclonal antibodies have aided in understanding sarcoma histogenesis.
- Malignant peripheral neuroectodermal tumors are recognized as a neural variant.
Purpose of the Study:
- To highlight advancements in small bone sarcoma treatment.
- To discuss the diagnostic and staging implications of the t(11;22) translocation.
- To review therapeutic strategies for disseminated disease.
Main Methods:
- Review of current treatment modalities including chemotherapy, surgery, and radiation.
- Application of monoclonal antibodies for tumor characterization.
- Molecular cloning and detection of the t(11;22) translocation breakpoint.
- Analysis of high-dose chemotherapy with stem cell rescue for advanced disease.
Main Results:
- Intensive combination chemotherapy and local control enhance disease-free survival.
- The t(11;22) translocation is a constant feature, enabling molecular diagnostics.
- High-dose therapy with stem cell rescue shows benefit in disseminated cases.
Conclusions:
- Molecular identification of the t(11;22) translocation represents a significant diagnostic advance.
- Further standardization of megatherapy regimens is needed for widespread application.
- Multimodal treatment strategies continue to improve outcomes for bone sarcomas.